Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
02/2003
02/13/2003WO2003011265A2 5-aminolevulinic acid and esters, in combination with another phtosensitizer, as photosensitizing agents in photochemotherapy, and their uses in treating wounds
02/13/2003WO2003011263A2 Use of a lactate salt for the treatment and prophylaxis of atherosclerosis
02/13/2003WO2003011262A2 Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with cgmp regulated processes
02/13/2003WO2003011255A1 Gastric retention controlled drug delivery system
02/13/2003WO2003011252A1 Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety
02/13/2003WO2003011230A2 Modified reoviral therapy
02/13/2003WO2003011226A2 Products and drug delivery vehicles
02/13/2003WO2003011222A2 Thrombin inhibitors
02/13/2003WO2003011207A2 Oral pharmaceutical composition comprising an active principle capable of being subjected to high effect during its first passage through the intestine
02/13/2003WO2003011106A2 Internal image antibodies for optical imaging and therapy
02/13/2003WO2002088146A3 ANTIDEPRESSANT INDOLETETRAHYDROPYRIDINE DERIVATIVES OF 2,3-DIHYDRO-7H-[1,4]DIOXINO[2,3-e]INDOLE
02/13/2003WO2002076995A3 2-amino-propanol derivatives
02/13/2003WO2002074231A3 Cosmetic and dermopharmaceutical compositions comprising standardised extracts of hierochloe odorata
02/13/2003WO2002062810A3 Linkable sialyl lewis x analogs
02/13/2003WO2002060454B1 Use of dinucleoside polyphosphate to stimulate removal of fluid in retinal disorders
02/13/2003WO2002051434A3 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders
02/13/2003WO2002047719A3 Survical promoting ncam binding and ncam ligand biding compounds
02/13/2003WO2002047604A3 Novel use of chalcone class compounds for inhibiting tumoral mass vascularization
02/13/2003WO2002038129A3 Delayed-release pharmaceutical formulations containing proinsulin c-peptide
02/13/2003WO2002036124A3 Treatment and method using loratadine and montelukast
02/13/2003WO2002034283A3 Vegh inhibitors and their use
02/13/2003WO2002032958A3 Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors
02/13/2003WO2002031115A3 Nucleic acid molecules and polypeptides for immune modulation
02/13/2003WO2002007753A3 Method for treating unstable angina pectoris
02/13/2003WO2001094951A9 Inhibitors of c-reactive protein induced inflammation
02/13/2003WO2001092567A3 Novel target genes for diseases of the heart
02/13/2003WO2001060398A8 Drugs for ameliorating impaired glucose tolerance
02/13/2003US20030033089 Substituted quinazolines and analogs and the use thereof
02/13/2003US20030032995 Thermotherapy via targeted delivery of nanoscale magnetic particles
02/13/2003US20030032917 Use of a blood-flow decrease preventing agent in conjunction with insufflating gas
02/13/2003US20030032834 Aminoalcohol derivatives
02/13/2003US20030032827 Lipoxin compounds and their use in treating cell proliferative disorders
02/13/2003US20030032804 Methods of treating periodontal disease
02/13/2003US20030032803 Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase
02/13/2003US20030032791 Nucleotide sequences coding polypeptide for use in the treatment of metabolic, reproductive and eating disorders
02/13/2003US20030032665 Method of inhibiting matrix metalloproteinases
02/13/2003US20030032663 Inhibition of the interaction of RAGE with its ligands; treatment acute and chronic inflammation, the development of diabetic late complications, Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
02/13/2003US20030032647 Aromatic nitrogen-containing 6-membered cyclic compounds
02/13/2003US20030032640 Novel composition
02/13/2003US20030032637 Agonists and antagonists of peripheral-type benzodiazepine receptors
02/13/2003US20030032634 Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
02/13/2003US20030032633 Use of the active fraction (-)- Olivil as an antioxidant or free radical scavenger.
02/13/2003US20030032630 Use of a 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-kappaB
02/13/2003US20030032626 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
02/13/2003US20030032616 Increasing cerebral bioavailability of drugs
02/13/2003US20030032581 Pharmaceuticals for treating obesity
02/13/2003US20030032179 Post-partum mammalian placenta, its use and placental stem cells therefrom
02/13/2003US20030032166 Aortic carboxypeptidase-like protein and nucleic acids encoding same
02/13/2003US20030031739 Dietary supplement of an aqueous extract of red vine leaves and carrier; relief of mild-to-moderate leg discomfort; flavonoids; antiinflammatory, -oxidant, -coagulant and -edema properties; hyaluronidase inhibitors
02/13/2003US20030031706 Carotenoid formulations, comprising a mixture of beta-carotene, lycopene and lutein
02/13/2003US20030031664 For therapy of pulmonary embolism, myocardial infarction, thrombosis or stroke
02/13/2003US20030031651 Methods and reagents for cell transplantation
02/13/2003US20030031627 For diagnosis and therapy
02/13/2003CA2808598A1 Antigenic polypeptides
02/13/2003CA2753329A1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
02/13/2003CA2468925A1 Platelet adp receptor inhibitors
02/13/2003CA2456192A1 Pyrazole-derived kinase inhibitors and uses thereof
02/13/2003CA2456187A1 Pyrazole-derived kinase inhibitors and uses thereof
02/13/2003CA2456096A1 Novel amine derivative having human .beta.-tryptase inhibitory activity and medecine containing the same
02/13/2003CA2456003A1 Regulator of calcineurin
02/13/2003CA2455963A1 Glp-1 exendin-4 peptide analogs and uses thereof
02/13/2003CA2455858A1 Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient
02/13/2003CA2455833A1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
02/13/2003CA2455772A1 Substituted isoindoles and their use
02/13/2003CA2455749A1 Butyric acid derivatives
02/13/2003CA2455728A1 As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
02/13/2003CA2455711A1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
02/13/2003CA2455598A1 Lipid constructs as therapeutic and imaging agents
02/13/2003CA2455398A1 Use of peptide fragments of the calcium channel .alpha.-1 subunit, optionally comprising mutations, for screening molecules of therapeutic interest
02/13/2003CA2455228A1 Antisense modulation of apolipoprotein b expression
02/13/2003CA2455194A1 Vascular endothelial growth factor isoform having anti-angiogenic activity
02/13/2003CA2455179A1 Androgen receptor modulators and methods of use thereof
02/13/2003CA2454937A1 Modulators of notch signalling for use in immunotherapy
02/13/2003CA2454935A1 Method for the nitration of phenolic compounds
02/13/2003CA2454753A1 Peptides having antiangiogenic activity
02/13/2003CA2454414A1 Use of 2-alkoxyphenyl-substituted imidazotriazinones
02/13/2003CA2454136A1 5-aminolevulinic acid and esters, in combination with another photosensitizer, as photosensitizing agents in photochemotherapy, and their uses in_treating wounds
02/13/2003CA2453937A1 Antigenic polypeptides
02/13/2003CA2453661A1 (-)-olivil as antioxidant
02/13/2003CA2453274A1 Thienopyrimidinediones and their use in the modulation of autoimmune disease
02/13/2003CA2452665A1 Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
02/13/2003CA2452529A1 Use of a blood-flow decrease preventing agent in conjunction with insufflating gas
02/13/2003CA2451942A1 Crystallized structure of type iv collagen nc1 domain hexamer
02/13/2003CA2451868A1 Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety
02/13/2003CA2451855A1 Oral pharmaceutical composition comprising an active principle capable of being subjected to high effect during its first passage through the intestine
02/12/2003EP1283260A1 Novel insulin/igf/relaxin family polypeptides and dnas thereof
02/12/2003EP1283216A1 Somatostatin analogues binding to all somatostatin receptor subtypes and their use
02/12/2003EP1283204A1 Methods for crystallization of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine n-carboxyanhydride
02/12/2003EP1283054A1 Drugs for complications of diabetes and neuropathy and utilization thereof
02/12/2003EP1283043A1 Ophthalmic solution
02/12/2003EP1282816A2 Improved assay techniques using nematode worms
02/12/2003EP1282706A2 Natrium-calcium exchanger protein
02/12/2003EP1282699A2 Splice-region antisense composition and method
02/12/2003EP1282643A2 Anti-inflammatory compounds and uses thereof
02/12/2003EP1282639A2 Polyamide nucleic acid derivatives, agents and methods for producing the same
02/12/2003EP1282624A1 Crf receptor antagonists and methods relating thereto
02/12/2003EP1282622A1 Crf receptor antagonists and methods relating thereto
02/12/2003EP1282621A1 Novel vitronectin receptor antagonists
02/12/2003EP1282617A1 Hydantoin derivatives with affinity for somatostatin receptors
02/12/2003EP1282614A1 Hydroxamic acid derivatives
1 ... 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 ... 1595